RE: RE: RE: Lets look at the last oneOne would think that the bulk samples would yield as much as 3.5 million dollars gross revenue for them and that this would be sufficient to justify a higher price per share. I will continue to hold since previously the work on the clone project has coincided with an increase in the share price. However, something seems amiss to the point where one has to wonder if they will delist.